Elanco Animal Health Incorporated - Bayer Aktiengesellschaft’s animal health business

Acquirer(s)

  • Elanco Animal Health Incorporated

Target(s)

  • Bayer Aktiengesellschaft’s animal health business

Summary

Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. In Australia, this includes:

  • pharmaceuticals, such as parasiticides and antimicrobials and analgesics,
  • specialty products, which include immunomodulators,
  • nutritionals, including vitamins, feed supplements and feed additives, and
  • other products including disinfectants.

Market inquiries

Submissions are invited from interested parties regarding the proposed acquisition. The closing date for submissions is 3 February 2020.

Submissions should be forwarded electronically (preferably in PDF format) to mergers@accc.gov.au with the title: "Submission re: Elanco/Bayer AG Animal Health - attention Alex Reed." Alternatively submissions may be mailed to the Merger Investigations Branch, ACCC, GPO Box 3131 Canberra ACT 2601.

Following 3 February 2020, queries regarding the ACCC's review may be addressed to Alex Reed at mergers@accc.gov.au.

For more details, please refer to the market inquiries letter below. 

ACCC correspondence

Document title Date

Timeline

DateEvent
20/12/2019ACCC commenced informal review under the Informal Merger Review Process Guidelines.
03/02/2020Closing date for submissions from interested parties.
12/03/2020Proposed date for announcement of ACCC’s findings (as outlined in the Informal Merger Review Process Guidelines, this may be a final decision or release of a Statement of Issues).

Project staff

  • Alex Reed

Contact email